The possibility to block C5 by the use of a monoclonal antibody against C5 in atypical hemolytic uremic syndrome (HUS) has significantly improved clinical outcomes for this patient group (137, 138). The gene discussed is C5; the disease is atypical hemolytic-uremic syndrome.